Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Convertible Note | Alive

Total Raised


Last Raised

$500K | 8 mos ago

About Axis

Axis is a platform for businesses to get the strategic information they need in their markets of operation. It offers stakeholder maps, dashboards covering the latest developments, regulation tracking, and macro and sector insights. It was founded in 2018 and is based in New York City, New York.

Axis Headquarters Location

New York, New York, 10024,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Axis News

05:45 EDT Targeting the CD47-SIRPA Axis in Oncology Analytical Tool 2022: 70 Companies and Partners Developing 81 CD47-SIRPA Axi...

Jun 9, 2022

News provided by Share this article Share this article Targeting the CD47-SIRPa axis is emerging as one of the most promising new cancer immunotherapy approaches seeking to target innate immune response. This report reveals intense global interest and a growing list of stakeholders operating in this field. Users of this report get an un-biased, fact driven analysis of the position of each molecule and commercial player, always kept up to date with twice weekly updates. This analytical tool is the must have handbook for any business developer, BI/CI operative or clinical developer who needs to be on top of this hot and fast moving area of immune-oncology. This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your drug surveillance and intelligence of the CD47-SIRPA axis in oncology, allowing you to power your decision making and advance your own interests. Keeping you "In the know" Simply put, our mission is to fuel your knowledge of immune-oncology, to make you the first to know about very early technologies and startups, emerging clinical trial results, drug approvals and the ever-changing competitive landscape. Targeting the CD47-SIRPA Axis in Oncology: Analytical Tool achieves this by continuously scanning development in CD47-SIRPA axis in oncology and reporting: Deals & Collaborations Drug Repositioning Opportunities For 20 years the author has supported better decision making across the oncology drug development industry. Your Targeting the CD47-SIRPA Axis in Oncology: Analytical Tool is based on two decades of proven methodology and transforms your computers desktop into a high capacity workbench within your area of choice. Even before launching this tool you have already eliminated the hundreds of hours of work needed to discover, process and piece together the thousands of sources that our team of oncology dedicated and highly experienced contents specialists have done on your behalf. Your Targeting the CD47-SIRPA Axis in Oncology: Analytical Tool covers more than 70 companies and partners who are today developing 81 CD47-SIRPA axis targeting drugs where of 76 are in active development in cancer across 28 different targets. Any data and/or analysis from the Analytical Tool is yours to keep and data/graphs/tables can be easily exported into Excel/PDF and various graphic formats for mixing with your own proprietary information. Let our expertise work for you With a simple point and click interface you can navigate the environment of current development, drill down into specific areas such as ongoing combination trials, biomarker analysis, selected scientific abstracts etc. and generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts). Any analysis generated by you is packed with presentation-ready graphs and tables to use in your reports and presentations. Your key to access development at the world-leading cancer meetings The Targeting the CD47-SIRPA Axis in Oncology: Analytical Tool is continuously updated according to twelve of the world's most influential meetings in oncology (AACR, ASCO, ASGCT, ASH, CMIT, EHA, EORTC-NCI-AACR, ESMO, SITC and BIO (International, Europe and Asia). If you are not able to attend any of the conferences in person, this Analytical Tool ensures that you are not missing out on the important take home messages you need to know about. Run combination therapy analysis like no other The Targeting the CD47-SIRPA Axis in Oncology: Analytical Tool delivers comprehensive combination therapy analysis, allowing you to analyze combination therapies from multiple perspectives; from a single drug to virtually any cross section of oncology drugs of interest. Unparalleled biomarker surveillance We also provide an outstanding oncology clinical biomarker surveillance & analysis, highlighting clinical phenotyping and patient stratification in trials. This analysis is based on our monitoring of the presence and usage of more than 1,000 biomarkers across tens of thousands of cancer clinical trials. Support and inspiration at your finger-tips You also have access to a great selection of How-to Training Videos showing best practice approaches to aspects such as competitive pipeline analysis right through to many real world case examples put forward by other users of our Analytical Tools. A tool to grow with and keep you informed Unlike a static report which just represents a particular snapshot in time, all of the Analytical Tools come with one year of online access to twice-weekly updates in both contents and features, pipeline alerts and online support etc. You can choose to renew your access to these updates and support on a yearly basis or go over to our industry leading full service platform covering all oncology drug development, 1stOncology. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact:

Axis Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Axis Rank

  • When was Axis founded?

    Axis was founded in 2018.

  • Where is Axis's headquarters?

    Axis's headquarters is located at New York.

  • What is Axis's latest funding round?

    Axis's latest funding round is Convertible Note.

  • How much did Axis raise?

    Axis raised a total of $500K.

  • Who are the investors of Axis?

    Investors of Axis include Y Combinator, Partech Partners, ICCP Venture Partners, Egan-Managed Capital, Global Ventures and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.